Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma

Gary Gross, Philip J. Thompson, Paul Chervinsky, Jennifer Vanden Burgt, Eugene Bleecker, Dick Briggs, Edwin Bronsky, Stuart Brooks, A. Sonia Buist, Edward Diamond, Robert Dockhorn, Thomas Edwards, Stanley Galant, Jay Grossman, F. Charles Hiller, Harold Kaiser, Mitchell Kaye, Michael Lawrence, Anthony Montanero, Richard MorrisRobert Nathan, Nancy Ostrom, David Pearlman, Bruce Prenner, Joe Ramsdell, Loren Southern, David Tinkelman, Frank Virant, Alan Wanderer

Research output: Contribution to journalArticle

110 Scopus citations

Abstract

Objective: The improved lung deposition of hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) extrafine aerosol compared with chlorofluorocarbon beclomethasone dipropionate (CFC-BDP) suggests that lower doses of HFA-BDP may be required to provide equivalent asthma control. The present study was undertaken to test this hypothesis. Design: A 10- to 12- day run-in period confirmed that patients met established criteria of at least moderate asthma and the asthma was inadequately controlled by current therapy (inhaled β-agonist and CFC-BDP [≤ 400 μg/d]). A short course of oral prednisone, 30 mg/d for 7 to 12 days, was followed to establish the patients were steroid responsive and to provide an 'in-study' baseline of 'optimal' asthma control. Patients: A total of 347 patients were then randomized to HFA-BDP 400 μg/d, CFC-BDP 800 μg/d, or HFA-placebo for 12 weeks. Results: Morning peak expiratory flow (AM PEF) measurements showed that HFA-BDP 400 μg/d achieved equivalent control of asthma to CFC-BDP 800 μg/d at all time intervals after oral steroid treatment. All other efficacy variables supported the AM PEF results and both active treatments were more effective than placebo. The safety profile of HFA-BDP compared favorably with that of CFC-BDP with no unexpected adverse events reported. Conclusions: These findings demonstrate that HFA-BDP provides equivalent control of moderate or moderately severe asthma as CFC-BDP in the population studied, but at half the total daily dose.

Original languageEnglish (US)
Pages (from-to)343-351
Number of pages9
JournalCHEST
Volume115
Issue number2
DOIs
StatePublished - Jan 1 1999

Keywords

  • Chlorofluorocarbon beclomethasone dipropionate
  • Hydrofluoroalkane-134a beclomethasone dipropionate
  • Moderate asthma

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma'. Together they form a unique fingerprint.

  • Cite this

    Gross, G., Thompson, P. J., Chervinsky, P., Vanden Burgt, J., Bleecker, E., Briggs, D., Bronsky, E., Brooks, S., Sonia Buist, A., Diamond, E., Dockhorn, R., Edwards, T., Galant, S., Grossman, J., Charles Hiller, F., Kaiser, H., Kaye, M., Lawrence, M., Montanero, A., ... Wanderer, A. (1999). Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma. CHEST, 115(2), 343-351. https://doi.org/10.1378/chest.115.2.343